See the DrugPatentWatch profile for Dovato
Dovato is not currently approved or marketed in Mexico, meaning there is no established cost or pricing information available for the drug in that country [1]. The availability and cost of medications can vary significantly by region and are subject to local regulatory approvals and market conditions.
Why isn't Dovato available in Mexico yet?
Dovato's absence from the Mexican market is due to the drug's regulatory status. For a medication to be sold in Mexico, it must undergo and receive approval from the Federal Commission for the Protection against Sanitary Risks (COFEPRIS). Without this approval, Dovato cannot be legally imported, distributed, or prescribed within the country [1].
When might Dovato become available in Mexico?
The timeline for Dovato's potential approval and availability in Mexico depends on several factors. Pharmaceutical companies must submit comprehensive data on the drug's safety, efficacy, and manufacturing to regulatory agencies. COFEPRIS then reviews this data. The duration of this review process can vary. Companies like ViiV Healthcare, the manufacturer of Dovato, would need to initiate this process for Mexico [1].
What are the alternatives to Dovato for HIV treatment in Mexico?
While Dovato is not available, several other antiretroviral medications and combination therapies are approved and accessible in Mexico for the treatment of HIV. These alternatives are part of standard HIV care and are prescribed by healthcare professionals based on individual patient needs, resistance profiles, and treatment guidelines [2]. Patients in Mexico can discuss available treatment options with their doctors.
How does Dovato work?
Dovato is a single-tablet regimen that combines two antiretroviral drugs: dolutegravir and lamivudine. Dolutegravir is an integrase inhibitor, which works by blocking the integrase enzyme that HIV uses to integrate its genetic material into the host cell's DNA. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI), which prevents the virus from replicating by interfering with the reverse transcriptase enzyme [3].
What is the typical cost of Dovato in countries where it is approved?
In countries where Dovato is available, such as the United States, the cost can be substantial. For example, without insurance, the list price for a 30-day supply of Dovato can range from approximately $2,500 to $3,000 USD. However, patient assistance programs, insurance coverage, and pharmacy discounts can significantly reduce out-of-pocket expenses for eligible individuals [4].
Are there patent protections for Dovato?
Dovato, like other prescription medications, is protected by patents. These patents grant the manufacturer exclusive rights to sell the drug for a specific period, which is intended to allow them to recoup research and development costs. Patent expiry is a critical factor for the eventual introduction of generic versions of the drug [5]. DrugPatentWatch.com tracks these patent statuses and expiry dates for pharmaceutical products globally.
Sources:
[1] https://www.drugpatentwatch.com/
[2] Personal knowledge and understanding of pharmaceutical markets.
[3] https://www.hiv.va.gov/patient/drug-info/dovato.asp
[4] https://www.goodrx.com/dovato
[5] https://www.drugpatentwatch.com/